ES2657549T3 - Piridopirazinas sustituidas como nuevos inhibidores de SYK - Google Patents

Piridopirazinas sustituidas como nuevos inhibidores de SYK Download PDF

Info

Publication number
ES2657549T3
ES2657549T3 ES12797167T ES12797167T ES2657549T3 ES 2657549 T3 ES2657549 T3 ES 2657549T3 ES 12797167 T ES12797167 T ES 12797167T ES 12797167 T ES12797167 T ES 12797167T ES 2657549 T3 ES2657549 T3 ES 2657549T3
Authority
ES
Spain
Prior art keywords
new
syk inhibitors
pyridopyrazines
substituted
substituted pyridopyrazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12797167T
Other languages
English (en)
Inventor
Wei-Guo Su
Wei Deng
Jianguo Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2657549(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of ES2657549T3 publication Critical patent/ES2657549T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Conductive Materials (AREA)

Abstract

Al menos un compuesto elegido de: **(Ver fórmula)** o su mezcla racémica, enantiómeros, diastereómeros, tautómeros o mezclas de los mismos, o al menos una sal farmacéuticamente aceptable de los mismos.
ES12797167T 2011-06-08 2012-06-07 Piridopirazinas sustituidas como nuevos inhibidores de SYK Active ES2657549T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2011/075431 WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 WO2012167733A1 (en) 2011-06-08 2012-06-07 Substituted pyridopyrazines as novel syk inhibitors

Publications (1)

Publication Number Publication Date
ES2657549T3 true ES2657549T3 (es) 2018-03-05

Family

ID=47295336

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12797167T Active ES2657549T3 (es) 2011-06-08 2012-06-07 Piridopirazinas sustituidas como nuevos inhibidores de SYK

Country Status (32)

Country Link
US (2) US9434726B2 (es)
EP (1) EP2718293B1 (es)
JP (2) JP5940148B2 (es)
KR (1) KR101571720B1 (es)
CN (1) CN103596952B (es)
AU (1) AU2012266941B2 (es)
BR (1) BR112013031405B1 (es)
CA (1) CA2836227C (es)
CL (1) CL2013003512A1 (es)
CY (1) CY1119953T1 (es)
DK (1) DK2718293T3 (es)
ES (1) ES2657549T3 (es)
HR (1) HRP20180139T1 (es)
HU (1) HUE037934T2 (es)
IL (1) IL229410A (es)
LT (1) LT2718293T (es)
MX (1) MX355671B (es)
MY (1) MY186599A (es)
NO (1) NO2718293T3 (es)
PE (1) PE20141167A1 (es)
PH (1) PH12013502434A1 (es)
PL (1) PL2718293T3 (es)
PT (1) PT2718293T (es)
RS (1) RS56901B1 (es)
RU (1) RU2569635C9 (es)
SG (1) SG195035A1 (es)
SI (1) SI2718293T1 (es)
SM (1) SMT201800057T1 (es)
TW (1) TWI494311B (es)
UA (1) UA111744C2 (es)
WO (2) WO2012167423A1 (es)
ZA (1) ZA201308947B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683716A1 (en) * 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
US20150307491A1 (en) * 2012-12-07 2015-10-29 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
WO2015123505A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
CA2942997C (en) 2014-03-19 2022-09-13 Boehringer Ingelheim International Gmbh Heteroaryl syk inhibitors
WO2016205633A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
WO2019018354A1 (en) * 2017-07-18 2019-01-24 Merck Patent Gmbh ANTAGONISTS OF TLR7 / 8 AND USES THEREOF
CN109422741A (zh) 2017-08-22 2019-03-05 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4186901A4 (en) * 2020-07-23 2024-06-12 Cytosinlab Therapeutics Co., Ltd. COMPOUND HAVING KINASE INHIBITORY ACTIVITY
AU2022284188A1 (en) * 2021-06-04 2023-11-30 Genentech, Inc. 2, 8-diazaspiro [4.5] decane compounds
WO2025208443A1 (en) * 2024-04-02 2025-10-09 Hutchmed Limited Methods of treatment warm autoimmune hemolytic anemia using sovleplenib

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1538907A4 (en) 2002-07-02 2008-12-24 Southern Res Inst FTSZ-HEMMER AND ITS USE
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
EP2459558A2 (en) * 2009-07-30 2012-06-06 Irm Llc Compounds and compositions as syk kinase inhibitors
ES2661850T3 (es) * 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
CN102822172A (zh) 2010-01-29 2012-12-12 贝林格尔.英格海姆国际有限公司 取代的二氮杂萘及其作为syk 激酶抑制剂的用途
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) * 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
CA2843022C (en) 2011-07-26 2019-09-24 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments

Also Published As

Publication number Publication date
JP6175484B2 (ja) 2017-08-02
AU2012266941A1 (en) 2013-11-28
MY186599A (en) 2021-07-29
NO2718293T3 (es) 2018-03-24
MX355671B (es) 2018-04-26
BR112013031405B1 (pt) 2021-12-21
JP2014516059A (ja) 2014-07-07
HUE037934T2 (hu) 2018-09-28
PT2718293T (pt) 2018-01-30
US20140121200A1 (en) 2014-05-01
TW201305160A (zh) 2013-02-01
CN103596952B (zh) 2016-05-04
AU2012266941B2 (en) 2016-03-31
MX2013014242A (es) 2014-04-14
WO2012167423A1 (en) 2012-12-13
CY1119953T1 (el) 2018-12-12
DK2718293T3 (da) 2018-01-29
CL2013003512A1 (es) 2014-07-18
IL229410A0 (en) 2014-01-30
ZA201308947B (en) 2020-02-26
JP5940148B2 (ja) 2016-06-29
HRP20180139T1 (hr) 2018-05-18
KR101571720B1 (ko) 2015-11-25
US20160324864A1 (en) 2016-11-10
SI2718293T1 (en) 2018-04-30
PL2718293T3 (pl) 2018-05-30
RS56901B1 (sr) 2018-05-31
US9434726B2 (en) 2016-09-06
EP2718293B1 (en) 2017-10-25
PE20141167A1 (es) 2014-09-03
PH12013502434A1 (en) 2014-01-13
SMT201800057T1 (it) 2018-03-08
WO2012167733A1 (en) 2012-12-13
IL229410A (en) 2017-08-31
BR112013031405A2 (pt) 2016-12-06
JP2016106100A (ja) 2016-06-16
UA111744C2 (uk) 2016-06-10
RU2569635C2 (ru) 2015-11-27
CA2836227A1 (en) 2012-12-13
CN103596952A (zh) 2014-02-19
EP2718293A1 (en) 2014-04-16
CA2836227C (en) 2016-08-16
RU2569635C9 (ru) 2016-07-10
HK1190143A1 (zh) 2014-06-27
KR20140025559A (ko) 2014-03-04
EP2718293A4 (en) 2014-12-03
US10052330B2 (en) 2018-08-21
NZ617765A (en) 2016-02-26
RU2013158996A (ru) 2015-07-20
TWI494311B (zh) 2015-08-01
SG195035A1 (en) 2013-12-30
LT2718293T (lt) 2018-02-12

Similar Documents

Publication Publication Date Title
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
UA113643C2 (xx) N-цикліламіди як нематоциди
EA201500173A1 (ru) Фунгицидные композиции
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
ECSP11011398A (es) Inhibidores de beta-secretasa
PH12015500263A1 (en) New bicyclic derivatives
CR20110432A (es) Pirimidinas fusionadas
MX373713B (es) Compuestos pirazolopirimidina.
UY34202A (es) Compuestos fungicidas 2-(2-clor0-4-(4-cloro-fenoxi)-fenil]-1-(1,2,4]triazol-1-1l-etanol alquilo sustituidos
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
IL228239A0 (en) 3,4-dihydro--pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MX2015012629A (es) Compuestos de imidazo piridina.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
EA201370149A1 (ru) Антагонисты рецептора
MX2015017156A (es) Inhibidores de bace.
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
MX387796B (es) Compuestos de aminocarbonilcarbamato.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina